1. Home
  2. ZLAB vs RNST Comparison

ZLAB vs RNST Comparison

Compare ZLAB & RNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • RNST
  • Stock Information
  • Founded
  • ZLAB 2013
  • RNST 1904
  • Country
  • ZLAB China
  • RNST United States
  • Employees
  • ZLAB N/A
  • RNST N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • RNST Major Banks
  • Sector
  • ZLAB Health Care
  • RNST Finance
  • Exchange
  • ZLAB Nasdaq
  • RNST Nasdaq
  • Market Cap
  • ZLAB 3.4B
  • RNST 3.7B
  • IPO Year
  • ZLAB 2017
  • RNST N/A
  • Fundamental
  • Price
  • ZLAB $32.58
  • RNST $37.78
  • Analyst Decision
  • ZLAB Buy
  • RNST Buy
  • Analyst Count
  • ZLAB 6
  • RNST 6
  • Target Price
  • ZLAB $57.22
  • RNST $42.20
  • AVG Volume (30 Days)
  • ZLAB 819.9K
  • RNST 515.2K
  • Earning Date
  • ZLAB 11-11-2025
  • RNST 10-21-2025
  • Dividend Yield
  • ZLAB N/A
  • RNST 2.33%
  • EPS Growth
  • ZLAB N/A
  • RNST N/A
  • EPS
  • ZLAB N/A
  • RNST 2.24
  • Revenue
  • ZLAB $427,799,000.00
  • RNST $735,575,000.00
  • Revenue This Year
  • ZLAB $42.62
  • RNST $42.66
  • Revenue Next Year
  • ZLAB $55.12
  • RNST $12.60
  • P/E Ratio
  • ZLAB N/A
  • RNST $16.86
  • Revenue Growth
  • ZLAB 32.56
  • RNST 17.23
  • 52 Week Low
  • ZLAB $20.17
  • RNST $26.97
  • 52 Week High
  • ZLAB $44.34
  • RNST $40.40
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 48.51
  • RNST 45.88
  • Support Level
  • ZLAB $31.68
  • RNST $37.10
  • Resistance Level
  • ZLAB $33.06
  • RNST $39.10
  • Average True Range (ATR)
  • ZLAB 1.34
  • RNST 0.87
  • MACD
  • ZLAB 0.21
  • RNST -0.23
  • Stochastic Oscillator
  • ZLAB 80.97
  • RNST 20.61

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About RNST Renasant Corporation

Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.

Share on Social Networks: